The promise of cancer immunotherapy and in particular checkpoint inhibitors that target the PD1 PDL1 signaling pathway is the topic of this episode.
We hear about the latest data presented at the 2015 annual meeting of the American Association for Cancer Research (AACR) in Philadelphia.
Interviews with Dr Julie Brahmer (Johns Hopkins), Dr Leisha Emens (Johns Hopkins) and Dr Ira Mellman (Genentech) take us on a journey that highlights some of the challenges and opportunities.
We also hear from Dr Suzanne Topalian (Johns Hopkins), Dr Antoni Ribas (UCLA) and Dr Pasi Jänne (Dana-Farber Cancer Institute).
Links to Papers Mentioned in the Podcast
Pembrolizumab versus Ipilimumab in Advanced Melanoma – The New England Journal of Medicine, April 19, 2015. DOI: 10.1056/NEJMoa1503093
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma – The New England Journal of Medicine, April 20, 2015. DOI: 10.1056/NEJMoa1414428
Oncology meets immunology: the cancer-immunity cycle – Immunity. 2013 Jul 25;39(1):1-10. DOI: 10.1016/j.immuni.2013.07.012 (Open Access).
Podcast Music
The music in this podcast episode is by electric violinist and composer David Schulman from his album Quiet Life Motel.
Sponsorship
This podcast episode is sponsored by Genentech. We’re grateful for their support.